BR112017014559A2 - polipeptídeo de ligação de il-17a, proteína de fusão ou conjugado, complexo, polinucleotídeo que codifica um polipeptídeo, e, composição - Google Patents

polipeptídeo de ligação de il-17a, proteína de fusão ou conjugado, complexo, polinucleotídeo que codifica um polipeptídeo, e, composição

Info

Publication number
BR112017014559A2
BR112017014559A2 BR112017014559-6A BR112017014559A BR112017014559A2 BR 112017014559 A2 BR112017014559 A2 BR 112017014559A2 BR 112017014559 A BR112017014559 A BR 112017014559A BR 112017014559 A2 BR112017014559 A2 BR 112017014559A2
Authority
BR
Brazil
Prior art keywords
polypeptide
fusion
complex
composition
polynucleotide encoding
Prior art date
Application number
BR112017014559-6A
Other languages
English (en)
Inventor
Frejd Fredrik
Feldwisch Joachim
Klint Susanne
GUDMUNDSDOTTER Lindvi
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of BR112017014559A2 publication Critical patent/BR112017014559A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Abstract

a presente revelação refere-se a uma classe de polipeptídeos projetados que tem uma afinidade de ligação para interleucina-17a (il-17a), e provê um polipeptídeo de ligação de il-17a compreendendo a sequência ex2dx4ax6x7eix10x11lpnl x16x17x18qx20x21afix25 x26lx28x29. também é revelada o uso de tal polipeptídeo de ligação de interleucina-17a como um agente diagnóstico, prognóstico e/ou terapêutico.
BR112017014559-6A 2015-01-12 2016-01-12 polipeptídeo de ligação de il-17a, proteína de fusão ou conjugado, complexo, polinucleotídeo que codifica um polipeptídeo, e, composição BR112017014559A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15150786 2015-01-12
EP15150786.0 2015-01-12
PCT/EP2016/050456 WO2016113246A1 (en) 2015-01-12 2016-01-12 Il-17a-binding polypeptides

Publications (1)

Publication Number Publication Date
BR112017014559A2 true BR112017014559A2 (pt) 2018-05-15

Family

ID=52339024

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014559-6A BR112017014559A2 (pt) 2015-01-12 2016-01-12 polipeptídeo de ligação de il-17a, proteína de fusão ou conjugado, complexo, polinucleotídeo que codifica um polipeptídeo, e, composição

Country Status (20)

Country Link
US (2) US10934335B2 (pt)
EP (2) EP3245224B1 (pt)
JP (3) JP6943764B2 (pt)
KR (1) KR20170116023A (pt)
CN (1) CN108064235A (pt)
AU (1) AU2016208161B2 (pt)
BR (1) BR112017014559A2 (pt)
CA (1) CA2972683A1 (pt)
DK (1) DK3245224T3 (pt)
ES (1) ES2822431T3 (pt)
HU (1) HUE052121T2 (pt)
IL (1) IL253004B (pt)
MX (1) MX2017008660A (pt)
MY (1) MY188784A (pt)
NZ (1) NZ732978A (pt)
PL (1) PL3245224T3 (pt)
PT (1) PT3245224T (pt)
RU (1) RU2749712C2 (pt)
WO (1) WO2016113246A1 (pt)
ZA (1) ZA201704366B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN108949789A (zh) * 2018-06-26 2018-12-07 山东兴瑞生物科技有限公司 抗gcc的核酸、其制备方法、具有该核酸的免疫细胞及其应用
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
CN111856029B (zh) * 2020-06-19 2023-09-26 北华大学 Il-17a蛋白在膀胱癌中的应用
WO2023152144A1 (en) * 2022-02-08 2023-08-17 Affibody Ab Protein z variants binding thymic stromal lymphopoietin and their medical use
WO2023196913A2 (en) * 2022-04-07 2023-10-12 Acelyrin, Inc. Methods of treating ankylosing spondylitis
WO2023196916A1 (en) * 2022-04-07 2023-10-12 Acelyrin, Inc. Methods of treating of hidradenitis suppurativa
CN116466095B (zh) * 2023-06-15 2023-09-01 朗肽生物制药股份有限公司 一种多肽及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
EA014298B1 (ru) 2005-12-13 2010-10-29 Эли Лилли Энд Компани Анти-il-17-антитела
AU2008281913B2 (en) 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
ATE527353T1 (de) * 2007-12-19 2011-10-15 Affibody Ab Pdgf-bindendes polypeptid aus protein a
TWI541021B (zh) * 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
AU2010288542B2 (en) * 2009-08-27 2014-05-22 Covagen Ag IL-17 binding compounds and medical uses thereof
EP2977088B1 (en) * 2010-03-08 2017-08-02 GE Healthcare BioProcess R&D AB Immunoglobulin g fc region binding polypeptide
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EP2597102A1 (en) * 2011-11-25 2013-05-29 Covagen AG A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
SI2817329T1 (sl) * 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab (Publ) Polipeptidi, ki se vežejo na človeški komplement c5
EP2711016A1 (en) * 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
KR102123457B1 (ko) 2012-09-25 2020-06-16 애피바디 에이비 알부민 결합 폴리펩타이드
CN104854127B (zh) * 2012-10-25 2020-12-25 阿菲博迪公司 白蛋白结合多肽
WO2014113804A1 (en) * 2013-01-21 2014-07-24 Abbvie Inc. Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease
CN105209482B (zh) 2013-03-15 2022-04-29 阿菲博迪公司 新的多肽
EP3083675B1 (en) 2013-12-20 2018-03-07 Affibody AB Engineered albumin binding polypeptide

Also Published As

Publication number Publication date
US20210253659A1 (en) 2021-08-19
CN108064235A (zh) 2018-05-22
IL253004A0 (en) 2017-08-31
JP7456024B2 (ja) 2024-03-26
JP2021073174A (ja) 2021-05-13
EP3245224B1 (en) 2020-07-15
JP6943764B2 (ja) 2021-10-06
IL253004B (en) 2021-06-30
AU2016208161B2 (en) 2020-01-16
US10934335B2 (en) 2021-03-02
RU2749712C2 (ru) 2021-06-16
DK3245224T3 (da) 2020-09-21
JP7208963B2 (ja) 2023-01-19
EP3738976A1 (en) 2020-11-18
CA2972683A1 (en) 2016-07-21
RU2017127012A3 (pt) 2019-06-24
EP3245224A1 (en) 2017-11-22
US20170362290A1 (en) 2017-12-21
RU2017127012A (ru) 2019-02-14
MX2017008660A (es) 2017-11-17
HUE052121T2 (hu) 2021-04-28
MY188784A (en) 2021-12-31
AU2016208161A1 (en) 2017-07-13
JP2018508186A (ja) 2018-03-29
JP2023052258A (ja) 2023-04-11
PL3245224T3 (pl) 2021-01-25
ZA201704366B (en) 2022-09-28
PT3245224T (pt) 2020-10-08
NZ732978A (en) 2022-01-28
WO2016113246A1 (en) 2016-07-21
KR20170116023A (ko) 2017-10-18
ES2822431T3 (es) 2021-05-04

Similar Documents

Publication Publication Date Title
BR112017014559A2 (pt) polipeptídeo de ligação de il-17a, proteína de fusão ou conjugado, complexo, polinucleotídeo que codifica um polipeptídeo, e, composição
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
BR112018007017A2 (pt) polipeptídeos
MX2019001469A (es) Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2018014456A (es) Anticuerpos contra alfa-sinucleina y sus usos.
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
BR112018010720A2 (pt) agonistas do receptor de apelina e métodos de uso
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
MX2019013289A (es) Variantes de ligasa modificadas geneticamente.
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
BR112018011008A2 (pt) agonistas de cnp de liberação controlada com ligação a npr-c baixa
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
MX2019014504A (es) Inmunoglobulinas de union a agrecano.
EA201591421A1 (ru) Препараты полипептида фактора ix
PH12019502694A1 (en) Anti-trkb antibodies
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
MX2018013556A (es) Polipeptidos variantes con rendimiento mejorado y uso de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]